Legislation to increase access to breast and cervical cancer screening introduced in the Senate

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds

Four out of five people returning to the ACA Marketplace say their healthcare costs are “higher,” compared to last year, according to a survey conducted by Kaiser Family Foundation in mid-February and early March. More than half of respondents reported these costs (premiums, deductibles, co-pays, or coinsurance) were “a lot higher.”

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Cancer Policy

House bill proposes to exempt health care workers from H-1B visa $100,000 fee

The H–1Bs for Physicians and the Healthcare Workforce Act—introduced by Rep. Sanford D. Bishop, Jr. (D-GA) and Rep. Mike Lawler (R-NY)—would exempt physicians and health care workers from a recently imposed $100,000 fee now required to obtain an H-1B visa, which allows foreign nationals in “specialty occupations” to live and work in the U.S. The fee was previously $5,000 to $10,000.

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.

March 13, 2026

Vol.52 No.10

Legislation to increase access to breast and cervical cancer screening introduced in the Senate

YOU MAY BE INTERESTED IN

ACA Marketplace enrollees are pinched by steeper healthcare costs, KFF follow-up survey finds

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

House bill proposes to exempt health care workers from H-1B visa $100,000 fee

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

Renew today!

Subscriber content

Never miss an issue!

Login